KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accounts Payables: 2010-2025

Historic Accounts Payables for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $3.8 million.

  • Rigel Pharmaceuticals' Accounts Payables rose 0.81% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 0.81%. This contributed to the annual value of $3.3 million for FY2024, which is 53.25% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Accounts Payables is $3.8 million, which was down 47.24% from $7.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Accounts Payables' 5-year high stood at $22.5 million during Q4 2022, with a 5-year trough of $1.7 million in Q2 2021.
  • Over the past 3 years, Rigel Pharmaceuticals' median Accounts Payables value was $6.1 million (recorded in 2024), while the average stood at $5.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 493.10% in 2022, then crashed by 68.27% in 2023.
  • Rigel Pharmaceuticals' Accounts Payables (Quarterly) stood at $3.8 million in 2021, then spiked by 493.10% to $22.5 million in 2022, then plummeted by 68.27% to $7.1 million in 2023, then slumped by 53.25% to $3.3 million in 2024, then increased by 0.81% to $3.8 million in 2025.
  • Its Accounts Payables was $3.8 million in Q3 2025, compared to $7.3 million in Q2 2025 and $4.0 million in Q1 2025.